Does Affimed N.V. (NASDAQ:AFMD) Have Gas After Even Less Sellers Involved?

April 17, 2018 - By Henry Gaston

The stock of Affimed N.V. (NASDAQ:AFMD) registered a decrease of 17.93% in short interest. AFMD’s total short interest was 397,800 shares in April as published by FINRA. Its down 17.93% from 484,700 shares, reported previously. With 393,700 shares average volume, it will take short sellers 1 days to cover their AFMD’s short positions. The short interest to Affimed N.V.’s float is 1.57%.

It closed at $2.1 lastly. It is down 25.96% since April 17, 2017 and is downtrending. It has underperformed by 37.51% the S&P500.

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in Germany and internationally. The company has market cap of $131.02 million. The Company’s lead candidate is AFM13, a natural killer cell TandAb designed for the treatment of CD30-positive (CD30+) B- and T-cell malignancies, including Hodgkin lymphoma. It currently has negative earnings. The companyÂ’s product candidates include AFM24, a NK-cell that treats epidermal growth factor receptor expressing solid tumors, such as lung, head, neck, and colon cancers; AFM26, which binds to B-cell maturation antigen (BCMA) for the treatment of multiple myeloma; and Trispecific Abs for the treatment of multiple myeloma.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: